Athira Pharma rises on advancing Alzheimer's drug trial

LeonaBio

17/10/2022 13:48

** Athira Pharma's shares  ATHA.O  rise 2.5% to $3.29
premarket
    ** Co advances mid- to late-stage study of experimental drug
fosgonimeton in mild-to-moderate Alzheimer's disease patients
following review of interim data by an independent panel
overseeing the trial  urn:newsml:reuters.com:*:nGNX8fKbx3
    ** Co plans to complete enrolment in trial in mid-2023 and
expects to announce results in early 2024
    ** 2 of 6 brokerages rate the stock "buy" or higher, 4
"hold"; their median PT is $5
    ** Up to Friday's close, stock had fallen 75% YTD
 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))